{"id":"daratumumab-injection","safety":{"commonSideEffects":[{"rate":"48","effect":"Infusion-related reactions"},{"rate":"35","effect":"Fatigue"},{"rate":"30","effect":"Nausea"},{"rate":"25","effect":"Anemia"},{"rate":"20","effect":"Thrombocytopenia"},{"rate":"18","effect":"Neutropenia"},{"rate":"15","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daratumumab targets CD38, a surface antigen highly expressed on malignant plasma cells in multiple myeloma. Upon binding, it induces cell death through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). This multi-modal mechanism makes it effective in both newly diagnosed and relapsed/refractory multiple myeloma.","oneSentence":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of plasma cells and multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:47.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"},{"name":"Light chain myeloma"}]},"trialDetails":[{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT07452198","phase":"PHASE3","title":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2026-03-09","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT07095452","phase":"PHASE2, PHASE3","title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-01-08","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT07485647","phase":"PHASE2","title":"Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing","status":"NOT_YET_RECRUITING","sponsor":"Eden Biltibo","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05083169","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-14","conditions":"Multiple Myeloma","enrollment":587},{"nctId":"NCT03301220","phase":"PHASE3","title":"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-07","conditions":"Smoldering Multiple Myeloma","enrollment":390},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT06353022","phase":"PHASE2","title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-06-26","conditions":"Multiple Myeloma","enrollment":103},{"nctId":"NCT01615029","phase":"PHASE1, PHASE2","title":"Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06-26","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT03901963","phase":"PHASE3","title":"A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-04-26","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT05552222","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-25","conditions":"Multiple Myeloma","enrollment":1590},{"nctId":"NCT04151667","phase":"PHASE2","title":"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-22","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":"Non-small Cell Lung Cancer With STK11/LKB1 Mutation","enrollment":8},{"nctId":"NCT04925193","phase":"PHASE2","title":"Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-11-18","conditions":"Multiple Myeloma in Relapse","enrollment":18},{"nctId":"NCT05289687","phase":"PHASE2","title":"Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL","status":"RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2023-05-25","conditions":"T-cell Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT04270175","phase":"PHASE2","title":"Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-04-14","conditions":"Amyloid, AL Amyloidosis, Refractory AL Amyloidosis","enrollment":15},{"nctId":"NCT07087314","phase":"PHASE2","title":"A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence","status":"RECRUITING","sponsor":"Mao Jianhua","startDate":"2025-08-25","conditions":"Nephrotic Syndrome in Children","enrollment":30},{"nctId":"NCT06953960","phase":"PHASE1, PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-23","conditions":"Multiple Myeloma","enrollment":130},{"nctId":"NCT06100237","phase":"PHASE2","title":"Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)","status":"RECRUITING","sponsor":"Carl Ola Landgren, MD, PhD","startDate":"2023-12-04","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT06892522","phase":"PHASE1, PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-30","conditions":"Multiple Myeloma","enrollment":440},{"nctId":"NCT07400744","phase":"PHASE1","title":"A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Multiple Myeloma","enrollment":102},{"nctId":"NCT05590377","phase":"PHASE1, PHASE2","title":"A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-23","conditions":"Multiple Myeloma","enrollment":15},{"nctId":"NCT05556616","phase":"PHASE1","title":"A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-12","conditions":"Multiple Myeloma","enrollment":15},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT03652064","phase":"PHASE3","title":"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-06","conditions":"Multiple Myeloma","enrollment":395},{"nctId":"NCT05250973","phase":"PHASE2","title":"A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-03-01","conditions":"Amyloidosis","enrollment":151},{"nctId":"NCT05455320","phase":"PHASE3","title":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-13","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":864},{"nctId":"NCT05695508","phase":"PHASE2","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","status":"RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2022-12-01","conditions":"Multiple Myeloma","enrollment":160},{"nctId":"NCT04824794","phase":"PHASE1, PHASE2","title":"GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies","status":"TERMINATED","sponsor":"Genmab","startDate":"2021-03-09","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)","enrollment":130},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT05259839","phase":"PHASE1","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-10-20","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":283},{"nctId":"NCT04009109","phase":"PHASE2","title":"Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2020-10-21","conditions":"Myeloma, Multiple","enrollment":79},{"nctId":"NCT04068597","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","status":"RECRUITING","sponsor":"CellCentric Ltd.","startDate":"2019-08-09","conditions":"Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma","enrollment":250},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT05145296","phase":"PHASE2","title":"The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2022-01-19","conditions":"Sensitisation, Highly Sensitised Dialysis Patients","enrollment":5},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT03201965","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-05","conditions":"Amyloidosis","enrollment":416},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT04070378","phase":"PHASE2","title":"Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Marc L Gordon, MD","startDate":"2019-11-06","conditions":"Alzheimer Disease","enrollment":16},{"nctId":"NCT05300451","phase":"PHASE2","title":"Daratumumab in HLA Desensitization Prior to Transplantation","status":"ENROLLING_BY_INVITATION","sponsor":"Barry A. Boilson","startDate":"2022-03-31","conditions":"Cardiac Transplant","enrollment":10},{"nctId":"NCT07075510","phase":"PHASE1, PHASE2","title":"Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-10-23","conditions":"Plasma Cell Disorder","enrollment":30},{"nctId":"NCT07221032","phase":"PHASE1","title":"FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":"Relapse Multiple Myeloma, Refractory Multiple Myeloma","enrollment":12},{"nctId":"NCT02252172","phase":"PHASE3","title":"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-02-16","conditions":"Multiple Myeloma","enrollment":737},{"nctId":"NCT06570915","phase":"PHASE2","title":"Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-01","conditions":"ALL, Adult","enrollment":20},{"nctId":"NCT04302324","phase":"PHASE2","title":"A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-10-28","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma","enrollment":9},{"nctId":"NCT06398457","phase":"EARLY_PHASE1","title":"Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-09-19","conditions":"Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML)","enrollment":8},{"nctId":"NCT07018050","phase":"PHASE2","title":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-12","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":160},{"nctId":"NCT05572229","phase":"PHASE2","title":"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-12-21","conditions":"Multiple Myeloma","enrollment":74},{"nctId":"NCT05654506","phase":"PHASE2","title":"Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-08-17","conditions":"Proliferative Glomerulonephritis With Monoclonal IgG Deposits","enrollment":40},{"nctId":"NCT04497961","phase":"PHASE2","title":"A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-08-28","conditions":"Multiple Myeloma","enrollment":95},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT07085728","phase":"PHASE2","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-08-11","conditions":"Myeloma Multiple","enrollment":74},{"nctId":"NCT06497738","phase":"","title":"A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-01","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT06952478","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-08-12","conditions":"Refractory or Relapsed Multiple Myeloma","enrollment":486},{"nctId":"NCT03314181","phase":"PHASE2","title":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-02","conditions":"Multiple Myeloma","enrollment":156},{"nctId":"NCT05308654","phase":"PHASE1","title":"A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-05-17","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":34},{"nctId":"NCT07107529","phase":"PHASE2","title":"Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.","status":"NOT_YET_RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2025-10","conditions":"Multiple Myeloma (MM)","enrollment":150},{"nctId":"NCT04643002","phase":"PHASE1, PHASE2","title":"Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-01-25","conditions":"Plasma Cell Myeloma Refractory","enrollment":258},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT07110662","phase":"PHASE1, PHASE2","title":"New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-10-29","conditions":"Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)","enrollment":9},{"nctId":"NCT06838962","phase":"PHASE2","title":"Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-01","conditions":"Immune Thrombocytopenia, Treatment","enrollment":30},{"nctId":"NCT07045909","phase":"PHASE2","title":"Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)","status":"RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2025-06-30","conditions":"De Novo Multiple Myeloma, Anitocabtagene Autoleucel","enrollment":30},{"nctId":"NCT07090954","phase":"PHASE1, PHASE2","title":"A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2025-08-31","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT06464991","phase":"PHASE3","title":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","status":"RECRUITING","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2024-03-27","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT04052880","phase":"PHASE2","title":"Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Larysa Sanchez","startDate":"2019-10-24","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":17},{"nctId":"NCT06867991","phase":"PHASE3","title":"Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis","status":"RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2024-11-08","conditions":"Anti-N-Methyl-D-Aspartate Receptor Encephalitis","enrollment":200},{"nctId":"NCT07063199","phase":"PHASE2","title":"Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08","conditions":"Immune Thrombocytopenia, Treatment","enrollment":30},{"nctId":"NCT06055075","phase":"PHASE1, PHASE2","title":"A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-12-12","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":19},{"nctId":"NCT05451771","phase":"PHASE1, PHASE2","title":"Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis","status":"RECRUITING","sponsor":"Rajshekhar Chakraborty, MD","startDate":"2022-10-26","conditions":"AL Amyloidosis","enrollment":53},{"nctId":"NCT04868838","phase":"PHASE2","title":"Daratumumab to Treat Active Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-04-20","conditions":"Lupus Nephritis","enrollment":12},{"nctId":"NCT07021677","phase":"PHASE2","title":"Use of a New Medicine \"Daratumumab\" to Treat Left-over Cancer in a Blood Cancer Called \"T Acute Lymphoblastic Leukemia\"","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2023-08-28","conditions":"T Acute Lymphoblastic Leukemia","enrollment":18},{"nctId":"NCT06629818","phase":"PHASE2","title":"Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-10-15","conditions":"Light Chain (AL) Amyloidosis","enrollment":36},{"nctId":"NCT05562882","phase":"PHASE2","title":"A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-10","conditions":"Immune Thrombocytopenia","enrollment":60},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT02519452","phase":"PHASE1","title":"A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-22","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT03158688","phase":"PHASE3","title":"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-06-13","conditions":"Relapsed Multiple Myeloma, Refractory Multiple Myeloma","enrollment":466},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT06931704","phase":"PHASE2","title":"Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-05-01","conditions":"Multiple Myeloma","enrollment":176},{"nctId":"NCT04166565","phase":"PHASE2","title":"Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-10-31","conditions":"Multiple Myeloma, Extramedullary Plasmacytoma","enrollment":41},{"nctId":"NCT06140966","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-10-20","conditions":"Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma","enrollment":54},{"nctId":"NCT04131309","phase":"PHASE2","title":"A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"Stichting European Myeloma Network","startDate":"2019-09-23","conditions":"Light Chain (AL) Amyloidosis, Stage 3B","enrollment":40},{"nctId":"NCT03871829","phase":"PHASE2","title":"Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-31","conditions":"Multiple Myeloma","enrollment":88},{"nctId":"NCT05004259","phase":"PHASE1","title":"The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2022-03-21","conditions":"Hemolytic Anemia","enrollment":2},{"nctId":"NCT06895512","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":386},{"nctId":"NCT05849610","phase":"PHASE2","title":"Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-09-21","conditions":"High-Risk de Novo Multiple Myeloma","enrollment":30},{"nctId":"NCT05243342","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2022-04-28","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT06371534","phase":"PHASE1","title":"A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-04-12","conditions":"Tumor","enrollment":228},{"nctId":"NCT04782687","phase":"PHASE2","title":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"US Oncology Research","startDate":"2021-09-10","conditions":"Multiple Myeloma, Myeloma Multiple, Kahler Disease","enrollment":73},{"nctId":"NCT04667663","phase":"PHASE1","title":"CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Trials Ireland","startDate":"2021-12-08","conditions":"Multiple Myeloma","enrollment":16},{"nctId":"NCT03319667","phase":"PHASE3","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2017-12-07","conditions":"Plasma Cell Myeloma","enrollment":475},{"nctId":"NCT06663943","phase":"PHASE1, PHASE2","title":"A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.","status":"NOT_YET_RECRUITING","sponsor":"Chao Ji","startDate":"2025-10-01","conditions":"Pemphigus Disease, Pemphigus Vulgaris (PV)","enrollment":100},{"nctId":"NCT04776018","phase":"PHASE1, PHASE2","title":"A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-04-20","conditions":"Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":27},{"nctId":"NCT06418477","phase":"PHASE2","title":"Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-06-15","conditions":"Monoclonal Gammopathy of Renal Significance","enrollment":20},{"nctId":"NCT06187441","phase":"PHASE3","title":"FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-05-14","conditions":"Multiple Myeloma","enrollment":599},{"nctId":"NCT06505369","phase":"PHASE2","title":"Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients","status":"RECRUITING","sponsor":"North Estonia Medical Centre","startDate":"2024-06-19","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05679258","phase":"PHASE1","title":"A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2023-01-31","conditions":"Multiple Myeloma","enrollment":172},{"nctId":"NCT03217812","phase":"PHASE3","title":"A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-23","conditions":"Multiple Myeloma","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DARZALEX (trade name)","Darzalex"],"phase":"phase_3","status":"active","brandName":"Daratumumab Injection","genericName":"Daratumumab Injection","companyName":"Charite University, Berlin, Germany","companyId":"charite-university-berlin-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daratumumab Injection is an antibody that targets the lymphocyte differentiation antigen CD38, and it is used to treat conditions such as relapsed or refractory multiple myeloma, multiple myeloma, non-Hodgkin lymphoma, B-cell lymphoma, and amyloidosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}